Following the successful buy-out of CRO Chiltern International earlier this year, the company is again celebrating after it was placed in the top half of the Europe's 500 listing
Chiltern International was placed 226th in the listing, which focuses on entrepreneurial achievement and fast growing European companies.
This marks the first entry for Chiltern in the Europe's 500 listing and, it says, represents a very successful three year run for the company.
Chiltern is one of the top three UK companies listed in the biotechnology and health sector out of 34 European entries from the industry.
There are 72 UK companies in the full listing with Chiltern placed as 37th.
Glenn Kerkhof, chief executive officer of Chiltern International is pleased to feature in the Europe's 500.
He commented: "It's been an exceptionally good year for Chiltern and being recognised among so many other respected European companies is a great achievement.
"This growth reflects our ever increasing global coverage and ability to conduct larger international clinical trials.
"As a high growth, job creating company, we are proud to offer a broad spectrum of career opportunities.
"It's particularly rewarding to be one of the highest placed UK companies on our inaugural entry into the listing".
Europe's 500 was first published in 1996 as an initiative of Europe's 500 - Entrepreneurs for Growth, a not-for profit membership and networking organisation representing high growth entrepreneurs.
It has been published on an annual basis ever since.
During this time, more than 4000 of Europe's high growth companies have received the accolade of being one of Europe's 500 champions of growth.
